Characteristics and outcomes of patients with relapsed follicular lymphoma following retreatment with second-line rituximab-containing chemotherapy

Click to increase image sizeClick to decrease image size

Acknowledgements

There was no funding source for this study. Medical writers/editors were not involved.

Disclosure statement

DS: honoraria and advisory boards for Abbvie, Seattle Genetics, Lundbeck, Roche, Celgene, Gilead, Janssen, Merck, Servier, Astra Zeneca, Sandoz.

AF: honoraria and advisory boards for Novartis, Abbvie, Amgen. Other payments from Lundbeck.

A. Peters: honoraria and advisory boards for Roche, Abbvie, Janssen, Lundbeck, Seattle Genetics, Gilead, ATARA.

IF: honoraria from Abbvie, Janssen, Lundbeck, Roche, Novartis; advisory boards for Abbvie, Astra Zeneca, BMS, Celgene, Gilead, Janssen, Merck, Novartis, Roche, Seattle Genetics.

A. Prica: honoraria and advisory boards for Astra Zeneca, Abbvie and Seattle Genetics.

JK: honoraria from Amgen, Astra Zeneca, BMS, Celgene, Gilead, Janssen, Karyopharm, Merck, Novartis, Roche, Seattle Genetics. Consultancy with Abbvie, BMS, Gilead, Karyopharm, Merck, Roche, Seattle Genetics.

LS: Honoraria and consultancy for Karyopharm, Hoffmann-La Roche/Genentech, Takeda, Verastem, TEVA Pharmaceutical Industries, Kite Pharma, Acerta, Astra Zeneca, Seattle Genetics, Janssen-Ortho, Merck, Abbvie, Amgen, Apobiologix, Celgene, Gilead, TG Therapeutics, Lundbeck. Research funding from Morphosys and Abbvie.

DV: honoraria and advisory boards for Roche, Lundbeck, Janssen, Celgene, Seattle Genetics, Astra Zeneca, Gilead, Abbvie, Nanostring.

Author contributions

JL, JK, and DV designed the research. JL, AJ, and DV analyzed data. All authors performed the research. All authors contributed data. JL and DV wrote the paper. All authors reviewed and approved the final manuscript.